Rhythm Pharmaceuticals, Inc. (RYTM) News

Rhythm Pharmaceuticals, Inc. (RYTM): $24.09

-0.74 (-2.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter RYTM News Items

RYTM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest RYTM News From Around the Web

Below are the latest news stories about Rhythm Pharmaceuticals Inc that investors may wish to consider to help them evaluate RYTM as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Phathom Pharmaceuticals (PHAT)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report) and Phathom Pharmaceuticals (PHAT – Research Report) with bullish sentiments. Rhythm Pharmaceuticals (RYTM) Ladenburg Thalmann & Co. analyst Michael Higgins maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $15.00. The company's shares closed last Tuesday at $8.49, close to its 52-week low of $6.02. According to TipRanks.

Christine Brown on TipRanks | March 2, 2022

Analysts Are Bullish on Top Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Establishment Labs Holdings (ESTA)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report) and Establishment Labs Holdings (ESTA – Research Report) with bullish sentiments. Rhythm Pharmaceuticals (RYTM) In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $40.00. The company's shares closed last Tuesday at $8.44, close to its 52-week low of $6.02. According to TipRanks.

Catie Powers on TipRanks | March 1, 2022

Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat at the Cowen & Co. 42nd Annual Health Care Conference on Tuesday, March 8, 2022 at 10:30 a.m. ET. A live audio webcast of the fireside chat will be avail

Yahoo | March 1, 2022

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 15% and 6.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 1, 2022

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results

-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – -- Enrollment completed in Phase 2 trial evaluating setmelanotide in patients with hypothalamic obesity -- -- IMCIVREE fourth quarter sales of $1.8M and 2021 sales of $3.2M – -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica

Yahoo | March 1, 2022

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Bardet-Biedl Syndrome and Alström Syndrome

-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the EMA -- BOSTON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) has extended by t

Yahoo | February 24, 2022

Rhythm Pharmaceuticals Announces Promotions within its Executive Leadership Team

BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the promotions of Joe Shulman to Chief Technical Officer, Patrick Kleyn, Ph.D., to Senior Vice President and Head of Translational Research and Development, and Elisabeth Crönert-Bendell, M.D., to Senior Vice President and Head of Strategy. “We are pleased to a

Yahoo | February 23, 2022

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022

BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, March 1, 2022 to report its fourth quarter and full year 2021 financial results and provide a corporate update. To access the live conference call, please dial (844) 498-0570 (dome

Yahoo | February 22, 2022

Rhythm Pharmaceuticals Announces Positive Interim Data from Long-term Extension Study of Setmelanotide in Bardet-Biedl Syndrome (BBS)

-- Patients with BBS achieved deepened and sustained weight loss at 24 months on setmelanotide therapy -- -- Company to provide update on U.S. BBS commercial readiness during virtual event today at 4 p.m. ET -- BOSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced positive interim data from its long-term extension

Yahoo | February 16, 2022

Rhythm Pharmaceuticals to Host Virtual Bardet-Biedl Syndrome (BBS) Event on February 16

-- Key opinion leaders and patient caregiver to discuss patient experience -- -- Company to provide update on U.S. BBS commercial readiness during event for investors and analysts -- -- Prescription Drug User Fee Act (PDUFA) goal date for setmelanotide for patients with BBS of March 16, 2022 -- BOSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic di

Yahoo | February 8, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5359 seconds.